Treatment of rheumatoid arthritis using imatinib
CA 2473158 C · Owner: Joensuu, Heikki · Inventors: Joensuu, Heikki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
4-(4-methylpiperazin-1-ylmethyl)-N-4-methyl-3-(4-pyridin-3-yl)pyrimidin-2ylamino)phenyl-benzamide of the formula (I) or a pharmaceutically acceptable , salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 27, 2003 and granted June 11, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.